Brief: Harvard Apparatus Regenerative Tech says will need additional testing of hart-trachea
30/01/2015 21:55
Jan 30 (Reuters) - Harvard Apparatus Regenerative Technology Inc HART.O : * Will need additional testing within ongoing preclinical large-animal model testing of hart-trachea * Expects to receive FDA approval to market hart-trachea in U.S. during first half of 2018, rather than by end of 2017 * Testing will require an additional 2 to 6 months beyond the company s previous estimates * Cta with mhra and ind with FDA expected to take place in H1 2016 rather than by end of 2015 - SEC filing * Source text for Eikon ID:nEOL48M1Kd * Further company coverage HART.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer